CymaBay down on Phase IIb NASH miss

CymaBay fell $5.04 (45%) to $6.05 on Tuesday after the company announced seladelpar missed the primary endpoint in a Phase IIb trial to treat NASH.

In 181 patients with biopsy-confirmed NASH, CymaBay Therapeutics Inc. (NASDAQ:CBAY) said the

Read the full 379 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE